William Blair Has Negative Estimate for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at William Blair lowered their FY2025 EPS estimates for shares of Jasper Therapeutics in a research note issued on Monday, November 10th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($5.23) for the year, down from their previous estimate of ($4.07). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. William Blair also issued estimates for Jasper Therapeutics’ Q4 2025 earnings at ($0.99) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.06) EPS and FY2028 earnings at ($3.12) EPS.

JSPR has been the subject of several other research reports. JMP Securities decreased their target price on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a research note on Monday, September 22nd. BTIG Research cut their target price on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Wednesday, October 8th. Evercore ISI cut their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, September 22nd. Finally, UBS Group reduced their target price on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.63.

Jasper Therapeutics Trading Up 4.1%

Shares of Jasper Therapeutics stock opened at $1.77 on Thursday. The business has a 50-day moving average price of $2.35 and a two-hundred day moving average price of $3.61. Jasper Therapeutics has a 1-year low of $1.60 and a 1-year high of $26.05. The company has a market cap of $28.76 million, a P/E ratio of -0.30 and a beta of 2.83.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.12).

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of JSPR. Propel Bio Management LLC purchased a new position in Jasper Therapeutics during the 3rd quarter worth $2,449,000. T. Rowe Price Investment Management Inc. lifted its position in shares of Jasper Therapeutics by 755.3% during the first quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company’s stock valued at $3,022,000 after purchasing an additional 620,592 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Jasper Therapeutics during the third quarter valued at about $1,450,000. Vanguard Group Inc. boosted its holdings in Jasper Therapeutics by 65.4% during the third quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock worth $2,458,000 after purchasing an additional 408,245 shares during the last quarter. Finally, Knott David M Jr purchased a new position in Jasper Therapeutics during the third quarter worth about $408,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Svetlana Lucas acquired 20,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $48,600.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at approximately $48,600. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Judith Anne Shizuru acquired 41,000 shares of the stock in a transaction dated Monday, September 22nd. The stock was bought at an average cost of $2.43 per share, with a total value of $99,630.00. Following the completion of the purchase, the director owned 156,901 shares of the company’s stock, valued at approximately $381,269.43. The trade was a 35.38% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 143,000 shares of company stock worth $347,490 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.